

References Biblio

- [1] Sieper J, Poddubnyy D. Axial spondyloarthritis. *Lancet* 2017;390:73–84.
- [2] Wendling D, Claudepierre P, Prati C, et al. Spondyloarthritis: a concept or a disease? *Joint Bone Spine* 2015;82:387–9.
- [3] Weiss PF, Colbert RA. Juvenile spondyloarthritis: a distinct form of juvenile arthritis. *Pediatr Clin North Am* 2018;65:675–90.
- [4] Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. *N Engl J Med* 2017;376:957–70.
- [5] Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis* 2011;70:25–31.
- [6] Wendling D, Lukas C, Prati C, et al. 2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. *Joint Bone Spine* 2018;85:275–84.
- [7] Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol* 2019;71:1599–613.
- [8] Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis* 2020;79:700–12.
- [9] Kerschbaumer A, Smolen JS, Dougados M, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis* 2020;79:778–86.
- [10] Kiltz U, Landewé RBM, van der Heijde D, et al. Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. *Ann Rheum Dis* 2020;79:193–201.
- [11] Gratacós J, Behrens F, Coates LC, et al. A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: a call to action. *Joint Bone Spine* 2021;88:105175.
- [12] Gladman DD, Helliwell PS, Poddubnyy D, et al. Updates on axial psoriatic arthritis from the 2020 GRAPPA Annual Meeting. *J Rheumatol* 2021;97:30–3.
- [13] López-Medina C, Molto A, Sieper J, et al. Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. *RMD Open* 2021;7:e001450.
- [14] Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. *Arthritis Rheumatol* 2019;71:846–63.
- [15] Lekpa FK, Wendling D, Claudepierre P. Spondyloarthritis: criteria, limitations, and perspectives throughout history. *Joint Bone Spine* 2015;82:390–3.
- [16] Gazeau P, Cornec D, Timsit MA, et al. Classification criteria versus physician's opinion for considering a patient with inflammatory back pain as suffering from spondyloarthritis. *Joint Bone Spine* 2018;85:85–91.
- [17] Goupille P, Wendling D. Toward a tailored therapeutic prescription for patients with axial spondyloarthritis. *Joint Bone Spine* 2021;88:105019.
- [18] Wendling D, Goupille P. Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis. *Immunotherapy* 2020;12:857–60.
- [19] Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. *Ann Rheum Dis* 2014;73:1455–61.
- [20] Robinson PC, Brown MA. The window of opportunity: a relevant concept for axial spondyloarthritis. *Arthritis Res Ther* 2014;16:109.
- [21] Claudepierre P. Spondyloarthritis: a window of opportunity? *Joint Bone Spine* 2014;81:197–9.
- [22] Carron P, Varkas G, Cypers H, et al. Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPE study. *Ann Rheum Dis* 2017;76:1389–95.
- [23] Haroon M, Gallagher P, Fitzgerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. *Ann Rheum Dis* 2015;74:1045–50.
- [24] Tillett W, Jadon D, Shaddick G, et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. *Ann Rheum Dis* 2013;72:1358–61.
- [25] Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). *Ann Rheum Dis* 2014;73:407–13.
- [26] Masson Behar V, Dougados M, Etcheto A, et al. Diagnostic delay in axial spondyloarthritis: a cross-sectional study of 432 patients. *Joint Bone Spine* 2017;84:467–71.
- [27] Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. *Arthritis Rheum* 2013;65:2645–54.
- [28] Beauvais C, Rodère M, Pereira B, et al. Essential knowledge for patients with rheumatoid arthritis or spondyloarthritis: results of a multicentric survey in France among health professionals and patients. *Joint Bone Spine* 2019;86:747–52.
- [29] Molto A, Gossec L, Poiraudou S, et al. Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA). *Rheumatology (Oxford)* 2021;60:888–95.
- [30] Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Ann Rheum Dis* 2018;77:3–17.
- [31] Wendling D, Prati C. Remission in axial spondyloarthritis: the ultimate treatment goal? *Joint Bone Spine* 2016;83:117–9.
- [32] Wendling D, Prati C, Sieper J. Disease activity in ankylosing spondylitis: the global therapeutic target. *Ann Rheum Dis* 2018;77:1095–6.
- [33] Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomized controlled trial. *Lancet* 2015;386:2489–98.
- [34] Molto A, López-Medina C, Van den Bosch FE, et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOPA trial. *Ann Rheum Dis* 2021;80:1436–44.
- [35] Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. *Ann Rheum Dis* 2016;75:811–8.
- [36] Wong A, Ye JY, Cook RJ, et al. Depression and anxiety reduce the probability of achieving a state of sustained minimal disease activity in patients with psoriatic arthritis. *Arthritis Care Res (Hoboken)* 2021, <http://dx.doi.org/10.1002/acr.24593>.
- [37] López-Medina C, Moltó A. Comorbid pain in axial spondyloarthritis, including fibromyalgia. *Ther Adv Musculoskelet Dis* 2020;12, <http://dx.doi.org/10.1177/1759720X20966123>.
- [38] Provan SA, Dean LE, Jones GT, et al. The changing states of fibromyalgia in patients with axial spondyloarthritis: results from BSRBR-AS. *Rheumatology (Oxford)* 2021;60:4121–9.
- [39] Liu V, Fong W, Kwan YH, et al. Residual disease burden in patients with axial spondyloarthritis and psoriatic arthritis despite low disease activity states in a multiethnic Asian population. *J Rheumatol* 2021;48:677–84.
- [40] Baillet A, Romand X, Pflimlin A, et al. Data to be collected for an optimal management of axial spondyloarthritis in daily practice: proposal from evidence-based and consensual approaches. *Joint Bone Spine* 2020;87:405–11.
- [41] Gossec L, Molto A, Romand X, et al. Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: a process based on literature reviews and expert consensus. *Joint Bone Spine* 2019;86:13–9.
- [42] Zurita Prada PA, Urrego Laurín CL, Guillén Astete CA, et al. Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review. *Clin Rheumatol* 2021;40:1673–86.
- [43] Gazel U, Ayan G, Solmaz D, et al. The impact of smoking on prevalence of psoriasis and psoriatic arthritis. *Rheumatology (Oxford)* 2020;59:2695–710.
- [44] Solmaz D, Kalyoncu U, Tinazzi I, et al. Current smoking is increased in axial psoriatic arthritis and radiographic sacroiliitis. *J Rheumatol* 2020;47, 13:54–8.
- [45] Højgaard P, Glinborg B, Hetland ML, et al. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. *Ann Rheum Dis* 2015;74:2130–6.
- [46] Ford AR, Siegel M, Bagel J, et al. Dietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation: a systematic review. *JAMA Dermatol* 2018;154:934–50.
- [47] Daïen C, Czernichow S, Letarouilly JG, et al. Dietary recommendations of the French Society for Rheumatology for patients with chronic inflammatory rheumatic diseases. *Joint Bone Spine* 2022;89:105319.
- [48]

- Moltó A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. *Ann Rheum Dis* 2016;75:1016–23.
- [49] Zhao SS, Robertson S, Reich T, et al. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. *Rheumatology (Oxford)* 2020;59:iv47–57.
- [50] Perez-Chada LM, Merola JF. Comorbidities associated with psoriatic arthritis: review and update. *Clin Immunol* 2020;214:108397.
- [51] Molto A, Gossec L, Poiraudau S, et al. Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: the results of the COMEDSPA prospective, controlled, oneyear randomized trial. *Semin Arthritis Rheum* 2020;50:701–8.
- [52] Verhoeven F, Prati C, Demougeot C, et al. Cardiovascular risk in psoriatic arthritis, a narrative review. *Joint Bone Spine* 2020;87:413–8.
- [53] Prati C, Demougeot C, Guillot X, et al. Vascular involvement in axial spondyloarthropathies. *Joint Bone Spine* 2019;86:159–63.
- [54] Liew JW, Huang IJ, Loudon DN, et al. Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis. *RMD Open* 2020;6:e001225.
- [55] Queiro R, Lorenzo A, Tejón P, et al. Obesity in psoriatic arthritis: comparative prevalence and associated factors. *Medicine (Baltimore)* 2019;98:e16400.
- [56] Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. *Arthritis Res Ther* 2019;21:17.
- [57] Ramírez J, Nieto-González JC, Curbelo Rodríguez R, et al. Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: a systematic review and meta-analysis. *Semin Arthritis Rheum* 2018;48:44–52.
- [58] Kwok TSH, Sutton M, Yang Ye J, et al. Prevalence and factors associated with osteoporosis and bone mineral density testing in psoriatic arthritis. *Arthritis Care Res (Hoboken)* 2020, <http://dx.doi.org/10.1002/acr.24538>.
- [59] Rausch Osthoff AK, Niedermann K, Braun J, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. *Ann Rheum Dis* 2018;77:1251–60.
- [60] Sveaas SH, Bilberg A, Berg IJ, et al. High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients. *Br J Sports Med* 2020;54:292–7.
- [61] Millner JR, Barron JS, Beinke KM, et al. Exercise for ankylosing spondylitis: an evidence-based consensus statement. *Semin Arthritis Rheum* 2016;45:411–27.
- [62] Kessler J, Chouk M, Ruban T, et al. Psoriatic arthritis and physical activity: a systematic review. *Clin Rheumatol* 2021;40:4379–89.
- [63] Bailly F, Cantagrel A, Bertin P, et al. Part of pain labelled neuropathic in rheumatic disease might be rather nociplastic. *RMD Open* 2020;6:e001326.
- [64] Kieskamp SC, Paap D, Carbo MJG, et al. Central sensitization, illness perception and obesity should be considered when interpreting disease activity in axial spondyloarthritis. *Rheumatology (Oxford)* 2021;60:4476–85.
- [65] Pathan EMI, Inman RD. Pain in axial spondyloarthritis: insights from immunology and brain imaging. *Rheum Dis Clin North Am* 2021;47:197–213.
- [66] Elsayy NA, Helal AH, Abd ElHamid HA, et al. Fibromyalgia in patients with psoriatic arthritis: impact on disease activity indices, fatigue and health-related quality of life. *Int J Rheum Dis* 2021;24:189–96.
- [67] Iannone F, Nivuori M, Fornaro M, et al. Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. *Rheumatology (Oxford)* 2020;59:1599–606.
- [68] Kroon FP, van der Burg LR, Ramiro S, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). *Cochrane Database Syst Rev* 2015:CD010952.
- [69] Goupille P, Wendling D. Are the recommendations for the use of anti-TNF drugs during axial spondyloarthritis relevant for non-radiographic forms? *Joint Bone Spine* 2020;87:381–3.
- [70] Wang R, Bathon JM, Ward MM. Nonsteroidal anti-inflammatory drugs as potential disease-modifying medications in axial spondyloarthritis. *Arthritis Rheumatol* 2020;72:518–28.
- [71] Dubreuil M, Louie-Gao Q, Pélouin CE, et al. Risk of myocardial infarction with use of selected nonsteroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. *Ann Rheum Dis* 2018;77:1137–42.
- [72] Liew JW, Ward MM, Reveille JD, et al. Nonsteroidal anti-inflammatory drug use and association with incident hypertension in ankylosing spondylitis. *Arthritis Care Res (Hoboken)* 2020;72:1645–52.
- [73] Park JH, Kwon OC, Park MC. Nonsteroidal anti-inflammatory drugs in patients with stable ankylosing spondylitis receiving tumor necrosis factor inhibitor: continued vs. withdrawn. *Clin Rheumatol* 2020;39:3669–75.
- [74] Dhir V, Mishra D, Samanta J. Glucocorticoids in spondyloarthritis – systematic review and real-world analysis. *Rheumatology (Oxford)* 2021;60:4463–75.
- [75] Haroon M, Ahmad M, Baig MN, et al. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study. *Arthritis Res Ther* 2018;20:73.
- [76] Wendling D. Local sacroiliac injections in the treatment of spondyloarthritis. What is the evidence? *Joint Bone Spine* 2020;87:209–13.

- [77] Lee TH, Koo BS, Nam B, et al. Conventional disease-modifying antirheumatic drugs therapy may not slow spinal radiographic progression in ankylosing spondylitis: results from an 18-year longitudinal dataset. *Ther Adv Musculoskelet Dis* 2020;12, <http://dx.doi.org/10.1177/1759720X20975912>.
- [78] Ducourau E, Rispen S, Samain M, et al. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. *RMD Open* 2020;6:e001047.
- [79] Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. *Ann Rheum Dis* 2020;79:1310–9.
- [80] McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. *Lancet* 2020;395:1496–505.
- [81] Wendling D, Verhoeven F, Prati C. Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. *Expert Opin Biol Ther* 2019;19:55–64.
- [82] Atzeni F, Carriero A, Boccassini L, et al. Anti-IL-17 agents in the treatment of axial spondyloarthritis. *Immunotargets Ther* 2021;10:141–53.
- [83] Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. *Arthritis Rheumatol* 2021;73:110–20.
- [84] Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. *Lancet* 2020;395:53–64.
- [85] Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. *Ann Rheum Dis* 2020;80:582–90.
- [86] van der Heijde D, Gensler LS, Deodhar A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. *Ann Rheum Dis* 2020;79:595–604.
- [87] Wei JC, Kim TH, Kishimoto M, et al. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. *Ann Rheum Dis* 2021;80:1014–21.
- [88] Wendling D, Prati C, Chouk M, et al. Effects of anti-IL-23 and anti-IL-17: the hidden side of spondyloarthritis polymorphism? *Joint Bone Spine* 2020;87:5–7.
- [89] Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. *Arthritis Rheumatol* 2019;71:258–70.
- [90] Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. *Ann Rheum Dis* 2018;77:1295–302.
- [91] Taylor PC, van der Heijde D, Landewé R, et al. A phase III randomized study of apremilast, an oral phosphodiesterase 4 inhibitor, for active ankylosing spondylitis. *J Rheumatol* 2021;48:1259–67.
- [92] van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. *Lancet* 2019;394:2108–17.
- [93] Deodhar A, Sliwinski-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. *Ann Rheum Dis* 2021;80:1004–13.
- [94] Deodhar A, Ranza R, Ganz F, et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis and axial involvement. *Ann Rheum Dis* 2021;80:143–4.
- [95] van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. *Lancet* 2018;392:2378–87.
- [96] Aouad K, Ziade N, Baraliakos X. Structural progression in axial spondyloarthritis. *Joint Bone Spine* 2020;87:131–6.
- [97] Rusman T, van der Weijden MAC, Nurmohamed MT, et al. Is treatment in patients with suspected nonradiographic axial spondyloarthritis effective? Six-month results of a placebo-controlled trial. *Arthritis Rheumatol* 2021;73:806–15.
- [98] Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. *J Rheumatol* 2016;43:356–61.
- [99] Blair HA. Secukinumab: a review in psoriatic arthritis. *Drugs* 2021;81:483–94.
- [100] Ruyssen-Witrand A, Perry R, Watkins C, et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. *RMD Open* 2020;6:e001117.
- [101] Mekhail C, Chouk M, Prati C, et al. Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review. *Expert Rev Clin Pharmacol* 2020;13:505–19.
- [102] Letarouilly JG, Flachaire B, Labadie C, et al. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison. *Rheumatology (Oxford)* 2021;60:2773–82.
- [103] Wu D, Li C, Zhang S, et al. Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis. *Rheumatology (Oxford)* 2020;59:3172–80.
- [104] Campanaro F, Batticciotto A, Zaffaroni A, et al. JAK inhibitors and psoriatic arthritis: a systematic review and meta-analysis. *Autoimmun Rev* 2021;20:102902.
- [105] McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. *N Engl J Med* 2021;384:1227–39.
- [106] Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. *Ann Rheum Dis* 2014;73:1000–6.
- [107] Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. *Rheumatology (Oxford)* 2021;60:2109–21.
- [108] Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. *Ann Rheum Dis* 2017;76:1550–8.
- [109] Mease P, Sieper J, Van den Bosch F, et al. Randomized controlled trial of adalimumab in patients with non-psoriatic peripheral spondyloarthritis. *Arthritis Rheumatol* 2015;67:914–23.
- [110] Keeling S, Maksymowych WP. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. *Expert Rev Clin Immunol* 2021;13:1–15.
- [111] Kavanaugh A, Gladman DD, Edwards CJ, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. *Arthritis Res Ther* 2019;21:118.
- [112] Behrens F, Cañete JD, Olivieri I, et al. Tumour necrosis factor inhibitor monotherapy vs. combination with MTX in the treatment of PsA: a systematic review of the literature. *Rheumatology (Oxford)* 2015;54:915–26.
- [113] Combe B, Tsai TF, Huffstutter JE, et al. Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies. *Arthritis Res Ther* 2021;23:41.
- [114] Lindström U, Di Giuseppe D, Delcoigne B, et al. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15,332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. *Ann Rheum Dis* 2021;80:1410–8.
- [115] Simons N, Degboé Y, Barnette T, et al. Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes. *Clin Exp Rheumatol* 2020;38:508–15.
- [116] McGonagle D, McInnes IB, Deodhar A, et al. Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase-3 psoriatic arthritis studies. *Rheumatology (Oxford)* 2021;60:5337–50.
- [117] Araujo EG, Englbrecht M, Hoepken S, et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. *Semin Arthritis Rheum* 2019;48:632–7.
- [118] Vieira-Sousa E, Alves P, Rodrigues AM, et al. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of Golimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naïve patients with psoriatic arthritis. *Ann Rheum Dis* 2020;79:490–8.
- [119] Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, et al. Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. *RMD Open* 2017;3:e000524.
- [120] Michelsen B, Lindström U, Codreanu C, et al. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. *RMD Open* 2020;6:e001280.
- [121] Micheroli R, Tellenbach C, Scherer A, et al. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. *Ann Rheum Dis* 2020;79:1203–9.
- [122] Glinborg B, Lindström U, Di Giuseppe D, et al. One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in spondyloarthritis. *Arthritis Care Res (Hoboken)* 2020, <http://dx.doi.org/10.1002/acr.24523>.
- [123] Gratacós J, Pontes C, Juanola X, et al. Non-inferiority of dose reduction versus standard dosing of TNF inhibitors in axial spondyloarthritis. *Arthritis Res Ther* 2019;21:11.
- [124] Landewé RB, van der Heijde D, Dougados M, et al. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. *Ann Rheum Dis* 2020;79:920–8.
- [125] Lawson DO, Eraso M, Mbuagbaw L, et al. Tumor necrosis factor inhibitor dose reduction for axial spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials. *Arthritis Care Res (Hoboken)* 2021;73:861–72.

- [126] Lukas C, Tournadre A, Picot MC, et al. Feasibility of progressive anti-TNF tapering in axial spondyloarthritis patients in Low disease activity: results from the Multicenter non-inferiority prospective randomized controlled trial Spacing (OP0138). *Ann Rheum Dis* 2021;80:80–1.
- [127] Landewé RB, Gensler LS, Poddubnyy D, et al. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). *Ann Rheum Dis* 2021;80:1022–30.
- [128] Coates LC, Pillai SG, Tahir H, et al. Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study. *Arthritis Rheumatol* 2021;73:1663–72.
- [129]
- [130] Ward MM. Increased rates of both knee and hip arthroplasties in older patients with ankylosing spondylitis. *J Rheumatol* 2019;46:31–7.
- [131] Lu M-C, Koo M. *Arthritis Care Res (Hoboken)* 2018;70:1416–20.
- [132] Gao Q, Zhang Z, Shao T, et al. Predictor of surgical outcomes in ankylosing spondylitis cervical spinal fracture: an at least 2 years follow-up retrospective study. *Spine (Phila Pa 1976)* 2021;46:E31–6.
- [132] Xin Z, Zheng G, Huang P, et al. Clinical results and surgery tactics of spinal osteotomy for ankylosing spondylitis kyphosis: experience of 428 patients. *J Orthop Surg Res* 2019;14:330.